AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04870528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed electromagnetic field device
Description: the pulsed electromagnetic field device treatment parameters will be set as 15 Hz frequency, 20 gauss amplitude, and 20 minutes as total treatment duration.
Study NCT04870528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free weights for Strengthening Exercise
Description: • Parameters of the exercise program: Intensity : The weight or load the patients lifted is set at 50-60% of their individual 1RM , 3 sets of 10 repetitions during the first week. During the second week, the lifting load is increased to 70-75% (3 sets of 10 repetitions) of their individual 1RM and continued for weeks 2-6. After this, training intensity is increased to 80-85% of the 1 RM and implemented from weeks 7-8.~Frequency: 3 sessions per week for 8 weeks. Number of repetitions: 3 sets,10 repetitions in each set. Total treatment duration: 8 weeks
Study NCT04870528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free weights for Strengthening Exercise
Description: • Parameters of the exercise program: Intensity : The weight or load the patients lifted is set at 50-60% of their individual 1RM , 3 sets of 10 repetitions during the first week. During the second week, the lifting load is increased to 70-75% (3 sets of 10 repetitions) of their individual 1RM and continued for weeks 2-6. After this, training intensity is increased to 80-85% of the 1 RM and implemented from weeks 7-8.~Frequency: 3 sessions per week for 8 weeks. Number of repetitions: 3 sets,10 repetitions in each set. Total treatment duration: 8 weeks
Study NCT06037798 — intervention group
Intervention type: OTHER
Intervention: cranio-cervical flexion test with NOD
Description: testing the anterior neck muscles during a nodding movement and by using a dynamometer
Study NCT06359873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CHA2DS2-VASc score, C2HEST score, and left atrial diameter (LAD)
Description: CHA2DS2-VASc Score: Congestive heart failure (HF) \[1 point\], hypertension \[1 point\], age ≥ 75 years \[2 points\], diabetes \[1 point\], prior stroke or transient ischemic attack \[2 points\], vascular disease \[1 point\], age 65-74 years \[1 point\], and female gender\[1 point\].~C2HEST Score: Coronary artery disease or chronic obstructive pulmonary disease \[1 point each, 2 total points\]; hypertension \[1 point\]; elderly \[2 points for age ≥ 75 years\]; systolic HF \[2 points\]; and thyroid disease \[1 point for hyperthyroidism\]\[10\].~LAD: The LAD values of the enrolled patients were extracted by keyword search based on the results of echocardiography in the database.
Study NCT05779462 — intervention group
Intervention type: OTHER
Intervention: Dynamic MRI Sequence
Description: Addition of a Dynamic MRI Sequence during the MRI examination performed in routine care
Study NCT04808531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanaBis™
Description: NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC \& CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD
Study NCT04808531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Description: Oxycodone CR tablet is an opioid agonist supplied in 10 mg, 15 mg, 20 mg, 30 mg,40 mg, 60 mg and 80 mg tablets for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.
Study NCT04808531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Spray
Description: Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
Study NCT04808531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spray
Description: Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
Study NCT04808531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
Study NCT04808531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
Study NCT04808531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone IR
Description: Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.
Study NCT04808531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone IR
Description: Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.
Study NCT04808531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone IR
Description: Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.
Study NCT04291950 — intervention group
Intervention type: PROCEDURE
Intervention: Needle core biopsy
Description: Blood draws will be done in OR by research staff. Tissue will be obtained at the time of their definitive surgery or at the time of port placement. For women going to surgery first, four (4) 16-gauge core needle biopsies will be obtained by research staff after the tumor has been removed from the patient and the specimen is on the collection table in the OR.~For women who are getting neo-adjuvant therapy prior to surgery, the core needle biopsies will be collected at the time of port placement in the OR. The patient will be under light anesthesia for the port placement. Per standard care, we will also use local anesthetic for the needle core biopsy. Port placement requires ultrasound (US). We will take advantage of the US already available in the OR to guide the core needle biopsy. Within 30 minutes of procurement, the tissue from the biopsies will be flash frozen in liquid nitrogen by staff and taken to the lab.
Study NCT05352503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watching videos with nature images accompanied by nature sounds with virtual reality glasses
Description: The video with nature images accompanied by the sounds of nature with virtual reality glasses will be watched 3 times a day for at least 5 minutes for 2 days.
Study NCT05867238 — intervention group
Intervention type: OTHER
Intervention: Training stress management
Description: The stress management training included 1 day and a half day. It was given by a therapist trained in transactional analysis and a trainer from the nurse anaesthetist school. The training was based on cognitive behavioural stress management training and the use of stress management exercises: cardiac coherence, mindfulness meditation, muscle relaxation, mental imagery.
Study NCT05779475 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Participants will not receive any investigational treatment in this study.
Study NCT04610021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-FactorTM Bone graft
Description: In the i-Factor ™ group it will be placed longitudinally in the intertransverse area. Likewise, in both groups, only autologous and bench bone will be placed in the intersomatic cages. The vertebrae where the i-Factor ™ is placed will be noted on the data collection sheet.
Study NCT05467514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
Study NCT06190067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Plus PD-1 therapy
Description: Patients were treated by Azacytidine(75 mg/m2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8)
Study NCT05349929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelofen (generic name of Ibuprofen in Iran)
Description: Gelofen capsules, 400mg Ibuprofen, Dana pharma company, every 6hours
Study NCT05349929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anahil ( generic name of Bromelain in Iran)
Description: Anahil capsules,200 mg Bromelain, Permon Amin Health Company,every 6hours
Study NCT05349929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Therapy
Description: all the participants go under RCT.
Study NCT05479214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1gm tablet with the 2 main meals
Study NCT05479214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: subcutaneous insulin daily administration
Study NCT05595187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricuspid repair
Description: Tricuspid repair included suture placement and the type of prosthetic annuloplasty.
Study NCT04945603 — intervention group
Intervention type: OTHER
Intervention: Standard management according to international/national guidelines
Description: Standard management according to international/national guidelines. Observational study
Study NCT06360263 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Densah bur in combination with activated plasma albumin gel
Description: Simultaneous implant placement after transcrestal maxillary sinus lifting using densah burs in combination with activated plasma albumin gel.(APAG). A full mucoperiosteal flap will be elevated, and then reflected with periosteal elevator application of first densah bur (the narrowest) with densifying mood (reverse) counterclockwise, 800-1500 revolutions per minute with copious irrigation until the sinus is reached confirm bur position with a radiograph. Then a wider densah bur (3.0) is used with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.The sequential densah bur will be used with the same mode and bouncing motion to elevate the the sinus floor 3 mm maximum. After achieving the final planned osteotomy diameter, the osteotomy will be filled with APAG. Then, the desired implant length is inserted.
Study NCT06076421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fact box
Description: Fact boxes provide a tabular or graphical overview of the benefits and harms of the COVID-19 or influenza vaccination through transparent risk communication. The fact boxes are available for two different age groups each: COVID-19 vaccination for people aged 18 to 59 and over 60, influenza vaccination for people aged 16 to 64 and over 65 in Arabic, German, Russian and Turkish.
Study NCT05112536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.
Study NCT05112536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cylophosphamide
Description: Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
Study NCT05112536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
Study NCT05112536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.
Study NCT05112536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (Investigator discretion)
Description: Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).
Study NCT05112536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Investigator discretion)
Description: Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).
Study NCT04807907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Directed Speech (IDS) Video + IDS Wall Calendar
Description: IDS Video: The IDS video was developed by the research team. It is a simple animation with a voiceover describing the value of IDS and encouraging the viewer to speak to her babies and to tell family members to do so as well. The video has been translated into Dagbani and English (viewers select the language). They may choose to watch it twice.~Breastfeeding women are told by the surveyor following the video, For instance, you could talk to your baby in full sentences when your baby is breastfeeding.~Wall Calendar: The calendar contains images from the video of parents practicing IDS, and key facts about IDS in bullet points. The 12-month calendar contains an empty star next to each week that the respondent can fill in if they perform IDS at least once a day in that week. The calendar also provides a link to a Facebook page where the respondents can re-watch the video or show it to others (https://www.facebook.com/ghanababytalk/videos).
Study NCT05413382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biofresh® 4plus
Description: Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
Study NCT05413382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
Study NCT04707157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: given orally
Study NCT04707157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: given orally
Study NCT06044480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administration of a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.
Study NCT06044480 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of the same amount of saline solution instead of dexamethasone
Study NCT05012956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sacrocolpopexy
Description: During laparoscopic sacrocolpopexy, the anatomical position of the vaginal vault and cervix (if present) is restored by suturing a surgical mesh to the vaginal cuff or cervix and variable portions of the anterior and posterior vagina, while connecting the other end of the mesh to the anterior longitudinal ligament over the sacrum.
Study NCT05012956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gynecologic laparoscopic surgery
Description: Gynecologic laparoscopic surgery at UZ Leuven, other than sacrocolpopexy
Study NCT01899833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-Sestamibi
Description: An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.
Study NCT05914909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD-214
Description: AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
Study NCT05914909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05981833 — intervention group
Intervention type: DEVICE
Intervention: Repair with DAA (dermal allograft augmentation)
Description: Patients undergo rotator cuff repair with dermal allograft augmentation.
Study NCT05021250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol marking
Description: HCC patients treated with TACE and the tumor marked with lipiodol.
Study NCT04793542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lower-limb hot water immersion
Description: For a minimum of 30 minutes, 3 times a week for 8 consecutive weeks, participants will submerge their lower-limbs into 30-32°C (lukewarm) or 39-40°C (hot) water which will be measured with a supplied waterproof thermometer.
Study NCT04793542 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: lower-limb hot water immersion
Description: For a minimum of 30 minutes, 3 times a week for 8 consecutive weeks, participants will submerge their lower-limbs into 30-32°C (lukewarm) or 39-40°C (hot) water which will be measured with a supplied waterproof thermometer.
Study NCT05210530 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VCTX210A unit
Description: CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device
Study NCT05884203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caregiver socket
Description: A prosthetic socket whose shape was captured by a study helper using digital methods (i.e., 3D scanner). The digital file describing the socket dimensions will be sent to a central fabrication facility where the prosthetic socket will be manufactured.
Study NCT05884203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetist socket
Description: A prosthetic socket whose shape was captured by a prosthetist using traditional, hand casting methods. The hand cast will be plaster filled to create a positive model. A prosthetist socket will be fabricated over the positive model using thermoplastic materials.
Study NCT05170906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflex locomotion stimulus
Description: The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
Study NCT05170906 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham stimulus
Description: The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg.
Study NCT05114200 — intervention group
Intervention type: PROCEDURE
Intervention: Erector spinae plane block
Description: Patients will be placed in prone position. Mild sedation will be achieved by using 1-2 mg of midazolam and 50-75 µg of fentanyl iv. The application area will be visualized with General Electrics (GE) Logiq e Ultrasound device using 10-12 MHz linear probe or convex probe. Transverse process and erector spinae muscles will be visualised at the target vertebral level. Following local anesthesia (1-2 cc 2% lidocaine) application to the insertion site, a 20 gauge spinal needle will be inserted using the in-plane technique. The needle will be advanced up to the transverse process under ultrasound guidance. After confirming needle position with hydrodissection, 40 mg triamcinolone, 10 cc 0,5% bupivacaine, 10 cc radiopaque contrast agent solution will be injected. Imaging will performed in AP and lateral positions with fluoroscopy immediately and 30 minutes after the injection to evaluate intectate spread.
Study NCT05377047 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
Study NCT04891315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for soluble VAP-1 (sVAP-1).
Description: \~5ml blood will be taken and sVAP-1 will be measure by Enzyme linked Immunosorbent Assay
Study NCT05473403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Description: Administration of high doses of corticosteroids as early as possible. Patient non-responder to treatment should lead to listing for emergency liver transplantation (LT).
Study NCT05532774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI defocusing frame glasses
Description: AI defocusing frame glasses have the function of eye behavior management, which can delay the progression of myopia through scientific management of eye behavior including outdoor light exposure (≥2 hours/day), duration of continuous close eye use (30 seconds rest every 30 minutes) and close eye distance (one punch, one foot and one inch), etc.
Study NCT05259865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic test for drug response prediction
Description: There is interest in whether genetic analysis of how a given drug is processed for a patient can help with rational drug choices (i.e. most efficacious, with least side effects/interactions, in the fastest time). This appears to have some early support in cardiac, psychiatric and acute pain studies.~All participants enrolled in the study will provide consent and a buccal cell sample for genotyping and standard patient reported outcomes questionnaires at the beginning of the study.
Study NCT04933175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparil
Description: Fluzoparil: 150 mg, P.O, BID, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
Study NCT04933175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib: 8mg, P.O, qd, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
Study NCT05099952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of cheek cell and blood samples
Study NCT05099952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Meet with therapist
Study NCT05099952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in BBT-CI sessions
Study NCT05099952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study NCT05099952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear actigraphy watch
Study NCT05099952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies